Pichitra Lekdamrongkul1,2, Kanaungnit Pongthavornkamol3, Alex Molassiotis4, Aurawamon Sriyuktasuth5, Noppadol Siritanaratkul6, Natkamol Chansatitporn7. 1. Faculty of Nursing, Mahidol University, Bangkok, Thailand. 2. Ramathibodi School of Nursing, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand. 3. Department of Medical Nursing, Faculty of Nursing, Mahidol University, 2 Wanglang Rd, Siriraj, Bangkoknoi, Bangkok, 10700, Thailand. kanaungnit.pon@mahidol.ac.th. 4. School of Nursing, The Hong Kong Polytechnic University, Hung Hom, Hong Kong. 5. Department of Medical Nursing, Faculty of Nursing, Mahidol University, 2 Wanglang Rd, Siriraj, Bangkoknoi, Bangkok, 10700, Thailand. 6. Division of Hematology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Rd, Siriraj, Bangkoknoi, Bangkok, 10700, Thailand. 7. Department of Biostatistics, Faculty of Public Health, Mahidol University, 420/1 Ratchawithi Rd, Ratchathewi District, Bangkok, 10400, Thailand.
Abstract
PURPOSES: To investigate health-related quality of life (HR-QoL) and its influencing factors among non-Hodgkin's lymphoma (NHL) survivors after completion of primary treatment. METHODS: A cross-sectional study with 312 NHL survivors after completing primary treatment using self-reported data collected through face-to-face interviews or postal survey between May 2019 and December 2019. Sociodemographic factors, clinical characteristics, physical symptom distress, anxiety, depression, unmet supportive care needs, and adaptation (post-traumatic growth and post-traumatic stress disorder) were assessed. Data analysis included ANOVA tests to investigate HR-QoL among NHL survivors at different time points and GEE to assess predictors of HR-QoL. RESULTS: The mean score of HR-QoL was 136.05 (SD 19.12). HR-QoL scores reported by NHL survivors in phase I (6 months or less post-treatment) were significantly lower than those in phase II (> 6 months-4 years), phase III (> 4-9 years), and phase IV (over 9 years post-treatment). Regarding HR-QoL domains, NHL survivors in phase I had significantly lower physical well-being and functional well-being scores than those in phases II, III, and IV; and significantly lower lymphoma domain score than those in phase III. GEE analysis showed that physical symptom distress, anxiety, depression, unmet supportive care needs, poor adaptation, and receiving chemotherapy disrupted HR-QoL (all P < .001). CONCLUSIONS: Healthcare providers should re-prioritize intervention guidelines and survivorship care planning to promote HR-QoL among NHL survivors, particularly in phase I, through reducing physical and psychological symptom distress, addressing unmet needs, and enhancing adaptation outcomes.
PURPOSES: To investigate health-related quality of life (HR-QoL) and its influencing factors among non-Hodgkin's lymphoma (NHL) survivors after completion of primary treatment. METHODS: A cross-sectional study with 312 NHL survivors after completing primary treatment using self-reported data collected through face-to-face interviews or postal survey between May 2019 and December 2019. Sociodemographic factors, clinical characteristics, physical symptom distress, anxiety, depression, unmet supportive care needs, and adaptation (post-traumatic growth and post-traumatic stress disorder) were assessed. Data analysis included ANOVA tests to investigate HR-QoL among NHL survivors at different time points and GEE to assess predictors of HR-QoL. RESULTS: The mean score of HR-QoL was 136.05 (SD 19.12). HR-QoL scores reported by NHL survivors in phase I (6 months or less post-treatment) were significantly lower than those in phase II (> 6 months-4 years), phase III (> 4-9 years), and phase IV (over 9 years post-treatment). Regarding HR-QoL domains, NHL survivors in phase I had significantly lower physical well-being and functional well-being scores than those in phases II, III, and IV; and significantly lower lymphoma domain score than those in phase III. GEE analysis showed that physical symptom distress, anxiety, depression, unmet supportive care needs, poor adaptation, and receiving chemotherapy disrupted HR-QoL (all P < .001). CONCLUSIONS: Healthcare providers should re-prioritize intervention guidelines and survivorship care planning to promote HR-QoL among NHL survivors, particularly in phase I, through reducing physical and psychological symptom distress, addressing unmet needs, and enhancing adaptation outcomes.
Authors: Qiuling Shi; Tenbroeck G Smith; Jared D Michonski; Kevin D Stein; Chiewkwei Kaw; Charles S Cleeland Journal: Cancer Date: 2011-04-14 Impact factor: 6.860
Authors: Sophia K Smith; Sheryl Zimmerman; Christianna S Williams; John S Preisser; Elizabeth C Clipp Journal: J Clin Oncol Date: 2008-02-20 Impact factor: 44.544
Authors: Simone Oerlemans; Djamila E Issa; Esther C van den Broek; Marten R Nijziel; Jan Willem W Coebergh; Floortje Mols; Lonneke V van de Poll-Franse Journal: Eur J Haematol Date: 2014-04-26 Impact factor: 2.997
Authors: Danbee Kang; Juhee Cho; Im Ryung Kim; Mi Kyung Kim; Won Seog Kim; Seok Jin Kim Journal: Cancer Res Treat Date: 2017-11-09 Impact factor: 4.679